Boston Scientific
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $5,061,000 | $4,663,000 | $4,561,000 | $4,209,000 |
Gross Profit | 3,424,000 | 2,950,000 | 2,671,000 | 2,648,000 |
EBITDA | 1,367,000 | 1,217,000 | 1,071,000 | 1,058,000 |
EBIT | 1,031,000 | 892,000 | 723,000 | 751,000 |
Net Income | 793,000 | 674,000 | 566,000 | 469,000 |
Net Change In Cash | 5,061,000 | 4,663,000 | 4,561,000 | 4,209,000 |
Free Cash Flow | 1,096,000 | 354,000 | 1,163,000 | 698,000 |
Cash | 534,000 | 725,000 | 414,000 | 2,502,000 |
Basic Shares | 1,493,300 | 1,493,100 | 1,490,200 | 1,487,400 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $16,747,000 | $14,240,000 | $12,682,000 | $11,888,000 |
Gross Profit | 10,267,000 | 8,831,000 | 7,714,000 | 7,461,000 |
EBITDA | 3,938,000 | 3,453,000 | 2,741,000 | 2,518,000 |
EBIT | 2,669,000 | 2,257,000 | 1,605,000 | 1,425,000 |
Net Income | 1,854,000 | 1,593,000 | 698,000 | 1,040,000 |
Net Change In Cash | 16,747,000 | 14,240,000 | 12,682,000 | 11,888,000 |
Cost of Revenue | -1,033,000 | 178,000 | ||
Free Cash Flow | 2,645,000 | 1,703,000 | 914,000 | 1,316,000 |
Cash | 414,000 | 865,000 | 928,000 | 1,925,000 |
Basic Shares | 1,485,900 | 1,463,500 | 1,439,700 | 1,433,800 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $0.75 |
2025-03-31 | $0.75 |
2024-12-31 | $0.70 |
